source
- Vir Biotechnology appoints David Liu as chief medical officer to steer hepatitis D phase 3 and cancer programsVir Biotechnology announced the appointment of David Liu, M.D., Ph.D., as its new chief medical officer. Liu comes from a recent stint as CMO at Nuvation Bio and has held senior roles at AstraZene…
- Caribou Biosciences explores strategic alternatives, drawing interest as a reverse-merger candidateCaribou Biosciences, the cell‑therapy company co‑founded by CRISPR pioneer Jennifer Doudna, announced it is evaluating strategic alternatives as it faces a difficult financing environment. The com…